Abstract 810P
Background
Recent studies suggested that tumor size reduction by means of pc prior to radical surgery might improve survival outcomes (SO) in CC pts. Whether pc has a beneficial effect in CC pts undergoing radical surgery in the form of total mesometrial resection (TMMR) is unclear. Because of the prevention of intraoperative tumor spillage by performing a closed colpotomy is essential to all TMMR, we hypothesized that pc would not affect SO in TMMR pts.
Methods
We performed a retrospective analysis of data which was collected in the Leipzig Mesometrial Resection trial. All pts had been treated for primary CC staged IB1 – IVA (2018-FIGO) by open abdominal hysterectomy performed as total or extended mesometrial resection (TMMR/EMMR). Recurrence-free (RFS) and overall survival (OAS) were analyzed. Cox proportional hazards regression models (Cox-R) were built to define the effect of pc. RFS and OAS within the conization group were analyzed to determine whether there is a difference between R0 (tumor removed completely) and R1 (tumor removed incompletely) conization.
Results
542 pts were included, of which 202 had received pc. After 1:1 propensity score matching including 163 pts with conization and 163 controls, pc was associated with significantly increased RFS (95.6% vs. 82.3%, HR 3.2, p<0.001) and OAS (99.2% vs. 85.6%, HR 6.4, p<0.001). In multivariable Cox-R pc was the only independent factor affecting RFS (HR 0.3, p<0.01). Analysis of the martingale residuals in a Cox regression null-model only including tumor-size revealed a continuous increase of recurrence risk with each increment in maximum tumor diameter for pts without pc, reaching a recurrence risk of 45% at a tumor size of 70 mm. In contrast, the recurrence risk for pts who had undergone pc plateaued at 12% at a tumor size of 37 mm. The sub analysis between R0 and R1 conization pts showed no difference in RFS and OAS.
Conclusions
In this study, pc was independently associated with improved survival in CC pts treated with TMMR/EMMR. Since intraoperative tumor spillage was avoided by closed colpotomy, factors other than the prevention of local tumor cell dissemination might play a role in improving survival. There is a need of further research to understand the concrete effect of pc to tumor biology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UKL-Universitätsklinikum Leipzig.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11